Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AVIDITY BIOSCIENCES, INC.

(RNA)
  Report
Delayed Nasdaq  -  04:00:01 2023-01-30 pm EST
22.77 USD   -2.98%
01/20Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
01/18Avidity Biosciences Says it Received FDA's Fast Track Designation for AOC 1020 to Treat Muscle-Weakening Disorder
MT
01/18Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Sector news Biopharmaceuticals
11:11aGlobal markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
10:29aUBS Adjusts Biogen's Price Target to $337 From $338, Maintains Buy Rating
MT
09:19aSector Update: Health Care Stocks in Red Pre-Bell Monday
MT
04:56aEisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
03:45aBiogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan
MT
03:29aSouth Korean Shares End Five-Day Rally; LG Display Swings to Net Loss in Q4
MT
01:56aSamsung Biologics Doubles Net Income in 2022
MT
01/29Zhifei Biological Products Renews Supply Deal With Merck
MT
01/29Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
RE
01/29Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen
RE
01/29Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in J..
CI
01/27Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre..
MT
01/27Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f..
MT
01/27Samsung Biologics Plans to Build an ADC Manufacturing Suite in Plant 4 to Start Product..
CI
01/26Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
DJ
01/26Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Au..
CI
01/25Lonza underscores growth prospects with share buy-back, dividend hike
RE
01/24Australian shares flat as miners offset gains in banks
RE
01/24Morgan Stanley Adjusts Price Target on Biogen to $345 From $325, Maintains Overweight R..
MT
01/23Biogen Says US FDA Sets Advisory Committee Meeting in March for Tofersen
MT
01/20Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts
RE
01/17Eisai, Biogen Seek Approval for Alzheimer's Drug in Japan
MT
01/17Trending: Wuxi Biologics Shareholder Plans Block Sale
DJ
01/17Australia shares end marginally lower as commodities drag
RE
01/17WuXi Biologics (Cayman) Substantial Shareholder to Place 56 Million Shares; Shares Slip..
MT
01/17Wuxi Biologics' Major Shareholder Plans to Sell 1.3% Stake
CI
01/17Wuxi Biologics Drops After Major Shareholder Plans to Sell 1.3% Stake
DJ
01/16Yen Boost, Prospect of Monetary Policy Shift Spook Japanese Traders; Daiichi Sankyo Fil..
MT
01/15Eisai files for approval of Alzheimer's drug in Japan
RE
01/15Eisai files for approval of Alzheimer's drug in Japan
RE
01/13RBC Trims Price Target on Biogen to $359 From $362, Maintains Outperform Rating
MT
01/11U.S. to announce list of drugs for pricing negotiations Sept. 1
RE
01/11Biogen, Eisai Seek Marketing Clearance in Europe for Early Alzheimer's Disease Drug
MT
01/10Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanem..
CI
01/09Transcript : Biogen Inc. Presents at 41st Annual J.P. Morgan Healthcare Confe..
CI
01/09Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron...
MS
01/09Trending: Biogen, Eisai Win FDA Nod for Alzheimer's Drug
DJ
01/09Oppenheimer Adjusts Biogen's Price Target to $320 From $315, Maintains Outperform Ratin..
MT
01/09Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts
RE
01/08Eisai, Biogen Get US Drug Regulator's Nod for Alzheimer's Drug
MT
01/06Eisai files for full FDA approval for Alzheimer's drug Leqembi
RE
01/06Wall St rallies as jobs, services data calm rate hike worries
RE
01/06Biogen's Leqembi Alzheimer's Medication Gets US FDA Accelerated Approval
MT
01/06Biogen's Leqembi Alzheimer's Medication Gets US FDA Accelerated Approval
MT
01/06Biogen's Alzheimer's Drug Approved by FDA, Shares to Resume Trading
MT
01/06Eisai says new Alzheimer's drug to cost $26,500 annually
RE
01/06Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under th..
CI
01/06Biogen Shares Halted For Pending News Stock Up 3.6% Before Halt
MT
01/06U.S. FDA approves Eisai, Biogen's Alzheimer's drug
RE
01/05Biogen splits R&D division ahead of key decision on Alzheimer's drug
RE
01/05SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Ant..
CI
01/05Biogen names Priya Singhal as head of development after splitting R&D division
RE
01/05Biogen Names Priya Singhal as Executive Vice President, Head of Development
CI
01/05U.S. new drug price exceeds $200,000 median in 2022
RE
01/05WuXi Biologics signs exclusive deal with GSK
AN
01/05Trending: Wuxi Biologics Licenses Tumor Antibodies to GSK
DJ
01/04Wuxi Biologics And Gsk Enter Into License Agreement On Multiple Novel Bi- & Multi-Speci..
RE
01/04Wuxi Biologics and GSK plc Enter into License Agreement on Multiple Novel Bi- & Multi-S..
CI
01/04Biogen, Alcyone Therapeutics to Collaborate on Medical Device to Deliver Antisense Olig..
MT
2022Biogen, FDA Interactions in Run-up to Aduhelm Approval Seen as 'Atypical,' US House Rep..
MT
2022U.S. FDA approves TG Therapeutics' multiple sclerosis drug
RE
2022Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report
RE
2022Biogen's Partner Eisai Begins Biologics License Application for Lecanemab in China
MT
2022Japan drugmaker Eisai's shares slump after report of 3rd death in Alzheimer's trial
RE
2022Sysmex says Japan approves blood test for Alzheimer's marker
RE
2022Biogen, Genentech Enter Into Agreement on Royalties, Potential Marketing of Investigati..
MT
2022Biogen Inc. Reaches Agreement with Genentech to Receive Royalties on the Potential Comm..
CI
2022CSL Limited Announces Positive CHMP Opinion for Etranacogene Dezaparvovec – Gene T..
CI
2022China's Property Support Measures Propel Rebound in Hong Kong Stocks; Wuxi Biologics Ju..
MT
2022Wuxi Biologics Shares Gain After Unit's Removal From U.S. 'Unverified List'
DJ
2022Chinese firms avert delisting as U.S. audit watchdog gets full inspection access
RE
2022Insider Sell: Biogen
MT
2022CSL Appoints CEO and Managing Director
MT
2022Australian shares track Wall Street higher, focus on U.S. inflation data
RE
2022CSL Limited Announces Management Changes
CI
2022CSL Limited Announces Chief Executive Officer Changes
CI
2022Australia's CSL Ltd names insider Paul McKenzie as CEO
RE
2022CSL Appoints Chief Operating Officer as CEO, MD From March 2023
DJ
2022Csl Limited Announces That Its Subsidiary, Csl Seqirus Finalized Global Collaboration a..
CI
2022Trending : Biogen Application for Actemra Biosimilar Accepted for Review
DJ
2022Correction to Biogen Actemra Biosimilar Article
DJ
2022Biogen Says FDA Accepted Arthritis Drug Candidate Application for Review
MT
2022Biogen: FDA Accepts Application for Actemra Biosimilar
DJ
2022U.S. Food and Drug Administration Accepts Biogen Inc.'s Biologics License Application f..
CI
2022Immutep Achieves Commercial Scale Production of Immunotherapy Candidate
MT
2022Biogen Inc., Sage Therapeutics, Inc. - Special Call
CI
2022Sage Therapeutics, Biogen Complete Rolling Submission of New Drug Application for Zuran..
MT
2022Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zu..
CI
2022Ionis Pharmaceuticals Says European Medicines Agency Accepts Application to Review Expe..
MT
2022Biogen's Marketing Application for Tofersen Accepted for Review by European Medicines A..
MT
2022Biogen Says European Medicines Agency Accepts Marketing Authorization Application of To..
MT
2022Biogen Inc. Announces European Medicines Agency Accepts Tofersen Marketing Authorizatio..
CI
2022UGI Says Talks to Sell French Energy Marketing Business Discontinued But Exit Still Pla..
MT
2022Transcript : Biogen Inc. Presents at 5th Annual Evercore ISI HealthCONx Confe..
CI
2022Atlantic Equities Adjusts Price Target on Biogen to $295 From $220, Maintains Neutral R..
MT
2022UBS Adjusts Biogen Price Target to $338 From $319, Maintains Buy Rating
MT
2022Analyst recommendations: Biogen, BAT, Hubbell, Liberty Global, P..
MS
2022Wall Street ends sharply higher after Powell comments
RE
2022Wall Street ends sharply higher after Powell comments
RE
2022Wall Street ends sharply higher after Powell comments
RE
Upcoming event on AVIDITY BIOSCIENCES, INC.